AstraZeneca beats expectations on cancer drug demand

AstraZeneca has today beaten first-quarter sales and profit expectations and maintained its 2026 outlook, as demand for its cancer drugs and investments in key markets helped the drugmaker navigate a complex geopolitical landscape.